Baxter International (NYSE: BAX) was upgraded by Standpoint Research from a “hold” rating to a “buy” rating in a research note issued on Friday. The firm currently has a $58.00 price target on the stock.
BAX has been the subject of a number of other recent research reports. Analysts at Raymond James (NYSE: RJF) initiated coverage on shares of Baxter International in a research note to investors on Wednesday, April 25th. They set an “outperform” rating on the stock. Separately, analysts at UBS AG (NYSE: UBS) cut their price target on shares of Baxter International from $66.00 to $64.00 in a research note to investors on Friday, April 20th. They now have a “buy” rating on the stock. Finally, analysts at UBS AG (NYSE: UBS) reiterated a “neutral” rating on shares of Baxter International in a research note to investors on Friday, April 20th.
Baxter International opened at 50.17 on Friday. Baxter International has a 1-year low of $47.55 and a 1-year high of $62.50. The company has a market cap of $27.623 billion and a price-to-earnings ratio of 12.74.
Baxter International last released its earnings data on Thursday, April 19th. The company reported $1.01 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.00 by $0.01. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Analysts expect that Baxter International will post $1.17 EPS next quarter.
Baxter International Inc. (Baxter,) is a global, diversified healthcare company. Baxter, through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.